Shamburg News · 8-K filed Nov 12, 2026, 4:45 PM EST
InspireMD Announces FDA Approval of CGuard Prime for Transcarotid Artery Revascularization Procedures
NSPR · InspireMD, Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
On November 12, 2026, InspireMD, Inc. announced that the U.S. Food and Drug Administration approved its Premarket Approval Supplement for the CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) procedures. The approval is supported by CGUARDIANS II pivotal trial data, which reported 100% acute device success and no deaths, strokes, myocardial infarctions, or stent thrombosis at 30 days. The company stated the approval doubles the platform's total addressable market, with access to more than 35,000 TCAR procedures performed annually in the United States.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, accession 0001493152-26-051453.
Written from the filing by Shamburg Markets. Figures are as reported by the company.